ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is Magnesium the Missing Link in Your Heart Healthy Routine?

Why the Mediterranean Diet Is so Successful

A Little Zinc Goes a Long Way

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

Vitamin D deficiency increases risk of chronic headache

Wearable biosensors can flag illness, Lyme disease, risk for diabetes; low airplane oxygen

VIDEO: The Best Brain Foods That Help Increase Your Memory!

More evidence for calorie restriction’s longevity effect

Iron (And More) For Lasting, Natural Energy

Affordable Care Act made cancer screening more accessible for millions, study finds

 
Print Page
Email Article

Ampligen for CFS Discussed at Department of Health and Human Services Meeting

  [ 203 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 17, 2004


PHILADELPHIA--(BUSINESS WIRE)--Nov. 15, 2004-

-Hemispherx Biopharma, Inc. (Amex:HEB) announced that the Department of Health and Human Services CFS Advisory Committee recently held its fifth meeting in Washington, D.C. Representatives from the Social Security Administration, the Food and Drug Administration and Health Resources and Services Administration were on hand to answer questions about Chronic Fatigue Syndrome (CFS) and the issues surrounding treatment and for the purposes of educating the public about the disease.

During this session, Utah clinician Dr. Lucinda Bateman made a presentation on behalf of her patients, who are enrolled in a double-blind study of Ampligen, a drug produced and sold by Hemispherx. Dr. Bateman believes that Ampligen offers substantial clinical benefit to "carefully selected patients." She reported that several of the patients at her site were able to return to more active lives and that there were relatively few side effects in her group. Dr. Bateman urged the FDA to approve the drug. Mary Schweitzer, Ph.D., echoed Dr. Bateman's support for approval of Ampligen, a drug that she has been able to benefit from through special cost recovery provisions that allow her to purchase the drug although it has not yet been approved for marketing.

Several of the speakers offered their appreciation for the committee's efforts and the dedication to important issues that committee members have demonstrated in their first year of work. Ampligen is an experimental, specifically configured, double-stranded RNA drug. The experimental product has completed a phase 3 clinical trial for the potential treatment of CFS. The FDA has already granted Ampligen Treatment IND Status and Orphan Drug Status. Treatment IND status was granted after an earlier reported study of 24 weeks duration consisting of 94 patients with severe CFS randomized to receive either Ampligen or placebo. Only governmental regulatory agencies can make a definitive determination that the presumed efficacy/safety ratio of any new drug supports its commercial introduction for any disorder, including potential CFS treatment.

About Hemispherx Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities. Its flagship products include Alferon N(R) and the experimental antivirals products, Ampligen(R) and Oragens(TM). These novel Alferon-N proteins, commercially available for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its four major technology platforms include large- and small-agent components for potential treatment of various chronic viral infections, and are being developed with various corporate, governmental and academic collaborators worldwide. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength FibroSleep™ Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Fighting Fatigue with Ground-breaking French Oak Wood Extract Fighting Fatigue with Ground-breaking French Oak Wood Extract
Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map